Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapy.
• ADCs combine monoclonal antibodies with cytotoxic drugs for precise tumor cell targeting.
• Cellular internalization of ADCs occurs through various endocytic pathways, including clathrin-mediated and caveolae-mediated endocytosis, as well as pinocytosis.

Purpose of the Study:

• To highlight the critical role of endocytosis and intracellular trafficking in ADC efficacy.
• To emphasize the need for optimizing conjugation strategies, linkers, and drug chemistry for successful tumor cell eradication.
• To review current strategies and challenges in developing potent engineered conjugates for enhanced cancer treatment.

Main Methods:

• Review of current literature on ADC internalization mechanisms.
• Analysis of endocytosis and intracellular trafficking pathways relevant to ADC function.
• Evaluation of conjugation strategies, linker technologies, and drug payloads.

Main Results:

• Endocytosis and intracellular trafficking pathways are pivotal for ADC-mediated drug delivery.
• Challenges remain in optimizing conjugation, linker stability, and drug release for maximal therapeutic effect.
• Recent advancements focus on engineering specific antibodies and conjugates to improve cancer cell targeting and treatment.

Conclusions:

• Efficiently harnessing endocytosis and intracellular trafficking pathways is essential for boosting ADC therapy efficacy.
• Designing potent engineered conjugates and biological entities is key to overcoming current challenges in cancer treatment.
• Further research into ADC trafficking and payload delivery will significantly advance targeted cancer therapies.